Search the GHTC website

Global health R&D delivers for Pennsylvania

US government investment in global health R&D has delivered

$1.2 billion
to Pennsylvania research institutions
14,600+ new jobs
for Pennsylvania
Pennsylvania's top USG-funded global health R&D institutions

Pennsylvania's top USG-funded global health R&D institutions

Magee-Womens Research Institute & Foundation
$318.6 million
University of Pennsylvania
$296 million
University of Pittsburgh
$172.2 million
Pennsylvania State University
$73.7 million
Drexel University
$43 million
Thomas Jefferson University
$40.5 million
Wistar Institute
$34.1 million
Undisclosed PA-based industry recipient
$27.3 million
OraSure Technologies
$26.9 million
Integral Molecular
$22.3 million
VGX Pharmaceuticals (formerly Viral Genomix)*
$20.9 million
Venatorx Pharmaceuticals
$16.5 million
Children's Hospital of Philadelphia
$16 million
Inovio Pharmaceuticals Inc.
$7.5 million
Fox Chase Chemical Diversity Center Inc. (FCCDC)
$6.2 million
Temple University
$5.1 million
Lubrizol Life Science Health (formerly Particle Sciences)
$4.9 million
Baruch S. Blumberg Institute
$4.7 million
Phelix Therapeutics
$4.2 million
Fox Chase Cancer Center
$4 million
$3.8 million
$3.7 million
PolyMedix Inc.*
$2.6 million
$2.1 million
Duquesne University
$1.6 million
Lehigh University
$1.5 million
Microbicide Trial Network
$1.1 million
Conifer Point Pharmaceuticals*
$1 million
Vital Probes Inc.*
$1 million
Bucknell University
$970 thousand
Philadelphia Research and Education Foundation
$789 thousand
$754 thousand
Lifeware Labs LLC
$655 thousand
TB Biosciences*
$638 thousand
Monell Chemical Senses Center
$621 thousand
$606 thousand
Carnegie Mellon University
$525 thousand
University of Pittsburgh Medical Center (including Pittsburgh Children's Hospital)
$502 thousand
Immunotope Inc.*
$408 thousand
Achillion Pharmaceuticals*
$403 thousand
Enantigen Therapeutics Inc.*
$385 thousand
Swarthmore College
$372 thousand
Abzyme Therapeutics LLC
$343 thousand
Vironika LLC
$341 thousand
Vaxform LLC
$324 thousand
JBS Science
$305 thousand
Villanova University
$301 thousand
Infini Fluidics
$293 thousand
Molecular Targeting Technologies Inc.
$256 thousand
Pennsylvania Drug Discovery Institute (PDDI)
$251 thousand
Sonitu Pharmaceuticals*
$195 thousand
Lenima Field Diagnostics
$185 thousand
Pittsburg State University
$185 thousand
Evrys Bio LLC
$175 thousand
Lipella Pharmaceuticals Inc.
$126 thousand
Transwall Office Systems
$116 thousand
Knoll International
$55 thousand

Pennsylvania's top areas of global health R&D by USG funding

Diarrheal diseases
Flioviral diseases (including Ebola, Marburg)
Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Reproductive health
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Emergent non-polio enteroviruses (including EV71, D68)
Henipaviral diseases (including Nipah)
Hepatitis B
Hepatitis C
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Rheumatic fever
Salmonella infections
Global health R&D at work in Pennsylvania

University of Pittsburgh researchers are studying whether bacteria-killing viruses, known as bacteriophages, can be used to treat bacterial infections, including those that are resistant to existing antibiotics. Bacteriophages, or phages for short, are viruses that are harmless to humans but kill bacteria by injecting their DNA into bacterial cells. The Pitt researchers have found success in using phage therapy to treat, under compassionate use protocol, a small number of patients with infections from mycobacterium, a family of bacteria that can be deadly to patients with compromised immune systems. Antibiotic drug resistance is a growing global challenge. Phage therapies offer promise as a new tool that could be used as a replacement to or in tandem with existing antibiotics to improve treatment outcomes.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PATH/Scott Areman